Latest news with #VCS
The Hindu
4 hours ago
- The Hindu
Vivo X Fold 5 and Vivo X200 FE launching on July 14: Expected features and price
Vivo gears for the launch of its second foldable phone, the X Fold 5, along with the FE edition of X200 on July 14 in India. The Vivo X Fold 5 will challenge the Samsung newly launched Galaxy Z Fold 7 whereas the X200 FE is going to offer an affordable option to experience Vivo's X series capabilities. The Vivo X Fold 5 is going to succeed the Vivo X Fold 3 launched last year. Vivo X Fold 5 claims to be 9.2 mm when folded and 4.3 mm when opened. It also claims a weight of 217 grams. The phone features a 4,500 nits peak brightness display. It is likely to have a 6.5 inch cover and over an 8 inch main display with a 120 Hz refresh rate. The Chinese smartphone maker has confirmed to use a 6,000 mAh battery in X Fold 5 along with an 80 W charger. It also supports 40 W wireless charging. (For top technology news of the day, subscribe to our tech newsletter Today's Cache) The X Fold 5 will run on the Snapdragon 8 Gen 3 processor with a likely pairing of up to 16 GB RAM and 512 GB storage. Vivo X Fold 5 will have a 50 MP VCS bionic main camera, a 50 MP ZEISS telephoto camera 3x optical zoom and up to 100x HyperZoom along with a 50 MP ultrawide lens. Vivo X Fold 5 will introduce a new tactile Shortcut button to access essential tools. It will have Gemini Assistant with Google along with the AI imaging suite. It will have tools like AI Image Expander, AI Magic Move, AI Erase, and AI Reflection Erase. The Vivo X200 FE is going to feature a 6.31 inch screen with an expected brightness of 4,500 nits and a 120 Hz refresh rate. It will have a 6,500 mAh battery with 90 W charging. It will feature Shield Glass reinforced with IP68 and IP69 ratings for dust and water resistance. Vivo X200 FE is going to run on the Mediatek Dimensity 9300+ chip with up to 12 GB RAM and 512 GB storage. It will operate on Funtouch OS. The X200 FE will sport a 50 MP ZEISS telephoto camera offering up to 100x zoom, a 50 MP main camera and an 8 MP ultrawide lens. X200 FE will come in Amber Yellow, Forest Blue and Luxe Grey. Vivo X Fold 5 is likely to get a premium pricing of around a lakh while the Vivo X200 FE might have a 70K price range in India.
Business Wire
4 days ago
- Business
- Business Wire
Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval
TORONTO--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. "This is a proud moment to see the world-class innovation from Alcon receive approval in Canada," said Dr. Rosa Braga-Mele, ophthalmologist and chair of Alcon's North America Cataract Core Advisory Board. Share 'Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us reach this milestone,' said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. 'We have a long legacy of engaging our customers throughout the research and development process to design bold innovations in ophthalmology. This approval is a significant milestone in delivering meaningful impact for Canadian Eye Care Professionals and patients.' Unity VCS is Alcon's most advanced vitreoretinal and cataract surgical innovations combined together in one integrated platform. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon's current leading systems, CONSTELLATION® Vision System for vitreoretinal and combined procedures, and CENTURION® Vision System with ACTIVE SENTRY® for cataract surgery. "The first time I used Unity VCS in a wet lab environment, I had a real 'wow' reaction," said Dr. Rosa Braga-Mele, ophthalmologist and chair of Alcon's North America Cataract Core Advisory Board. "This is a proud moment to see the world-class innovation from Alcon receive approval in Canada. I'm particularly excited about the stability of the fluidics and cutting efficiency of the platform, which is quite remarkable and will create considerable surgical efficiencies." Unity VCS leverages a novel phacoemulsification modality to deliver up to two times faster nucleus removal^ with 40% less energy* into the eye1, and a first-of-its-kind phaco handpiece that estimates temperature at the incision site3. In vitreoretinal advancements, the new technology offers cutting speeds of up to 30,000 cuts per minute, the world's fastest vitrectomy probe#,2,3. The platform offers surgical stability and efficiency with a unique proprietary fluidics system3. "As a global market leader in cataract and retina surgical products4,5,6, Alcon recognizes that the increasing demand for these procedures7,8,9 necessitates enhanced workflow efficiencies and excellent patient outcomes," said Jeroen Bastemeijer, General Manager, Alcon Canada. "Unity VCS builds on Alcon's expertise in surgical equipment with pioneering innovations for vitreoretinal and cataract surgery—driving advancements from cutting speeds to fluidics management, to ergonomics and workflow. We are thrilled to bring this latest breakthrough technology, Unity VCS, to Canadian clinics in 2026." Alcon has tested Unity VCS during investigational advisory wet lab sessions with more than 200 highly experienced surgeons from 30+ countries. Commercial launch of Unity VCS is expected in early 2026. Unity VCS is the latest innovation from the Alcon Vision Suite—a portfolio of innovative products designed to help Eye Care Professionals increase clinic and OR efficiency, and deliver exceptional patient experiences. The Alcon Vision Suite will continue to grow with cutting-edge Unity products that are expected to be introduced over the coming years, adding to our market-leading legacy products, which will continue to be available and serviceable. Unity VCS will be supported by Alcon's training, product maintenance, and Services teams. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at About UNITY VCS Indications / Intended Use3: The UNITY® VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser, this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. Please refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes. ^2x faster nucleus removal than OZIL Torsional phaco *Based on N=10 HPs, Artificial cataract lens IOP 55 mmHg vacuum of 450 mmHg #Compared to Constellation HYPERVIT 20k vitrectomy probe OZIL - Trademarks are the property of their respective owners. References Alcon Data on File, 2024 - REF-24379. Alcon Data on File, 2024 - REF-24644. Unity VCS User Manual 2024 – REF-24980. Market Scope 2023 Retinal Surgical Device Market Report, 2023. Market Scope 2023 Cataract Surgical Equipment Market Report, 2023. Market Scope 2024 IOL Market Report, 2024. CNIB – Blindness in Canada, Accessed December 2, 2024 - REF-19527. The Prevalence of Canadian Vision Loss and Cataract Surgery, 2019 - REF-01661. Conference Board of Canada - Ophthalmology in Canada: Why Vision Loss Should Not Be Overlooked, 2020 - REF-10834. Connect with us on Facebook LinkedIn
Leader Live
04-06-2025
- General
- Leader Live
Wrexham man urges others to volunteer for ambulance service
John Mackie, 56, from Rossett, volunteers with the Volunteer Car Service, transporting patients to and from hospital appointments in his own vehicle. He said: "I can honestly say it's one of the best things I have ever done, and it really is a rewarding role as I get to help people who are going through a very difficult time, just like my father was. 'It's so flexible and I can easily fit it in around my other hobbies and interests. "I give three days a week to being a VCS driver and I would encourage other people who have the spare time and a vehicle to consider becoming a volunteer." Mr Mackie, originally from Glasgow, spent 32 years working for frozen food retailer Iceland and was on the company's board of directors before taking early retirement. He said he was inspired to volunteer after supporting his father through cancer treatment. He said: "It all started for me after my father was diagnosed with cancer and I was taking him to and from the hospital for appointments and treatment. "I could see other patients in the waiting room who were waiting to be taken home and after seeing a post on social media about the VCS, it all fell into place, and I applied immediately." The Volunteer Car Service is one of several key roles supported by the Welsh Ambulance Service, which is celebrating the contribution of nearly 700 volunteers across Wales as part of Volunteers' Week. These include community first responders, community welfare responders, and volunteer car service drivers. Lee Brooks, executive director of operations, said: "Volunteers are an essential part of the Welsh Ambulance Service. "Their commitment and generosity directly impact thousands of patients every year, and we simply couldn't do what we do without them. "Volunteers' Week is a wonderful chance to recognise their incredible efforts, to celebrate the time and energy they selflessly give, and to thank them publicly for their continued support of their local communities." Community First Responders (CFRs) are trained to attend 999 calls and deliver life-saving first aid before an ambulance arrives. In 2024/25 alone, CFRs responded to more than 10,841 emergencies across Wales. Community Welfare Responders (CWRs) attend incidents that are not immediately life-threatening, providing live observations to control rooms so that patients can be monitored remotely by clinicians. CWRs recorded 1,045 attendances in the past year. The Volunteer Car Service supports patients attending regular medical appointments, including renal dialysis and oncology. Last year, VCS drivers completed 45,557 journeys and covered a total of 1,426,165 miles. Read more: Wrexham charity celebrates CEO's invitation to Buckingham Palace Wrexham baker receives award for 'outstanding contribution' to Welsh food industry Gareth Parry, operations manager for volunteering and community resilience, said: "Our fantastic volunteers play a vital role in supporting the trust, offering their time, skills, and compassion to strengthen patient care. "Their dedication ensures our service continues to provide the highest level of support to communities. "In return, they take on a challenging and highly rewarding role, becoming a vital part of #TeamWAST, while making a meaningful difference in people's lives." For more information on volunteering for the Welsh Ambulance Service, visit: Volunteer For Us - Welsh Ambulance Services University NHS Trust.
The Hindu
01-06-2025
- The Hindu
‘793 victims of crimes deprived of compensations owing to lack of funding by State government'
Nearly 800 victims of crimes, including minor girls and female victims of sexual offences, have been waiting for compensation for the past two years as the State government has failed to release adequate funds to the Karnataka State Legal Services Authority (KSLSA), which has the statutory power to disburse the compensation to eligible victims. As per data of the KSLSA, a total of around ₹30 crore is required to pay 793 victims of crime, who were found eligible to receive compensation as per provisions of the Code of Criminal Procedure (CrPC) and the Bharatiya Nagarik Suraksha Sanhita (BNSS). How much is required Of these 793 persons, 209 were found eligible for compensation during 2023-24 and 584 during 2024-25. As per the data, a total of around ₹8 crore is required to pay for 209 victims and ₹22 crore is needed to pay 584 persons, based on the assessment of compensation to which the victims or their family members are entitled to. As per the data, around 400 persons are likely to be added to the list of eligible victims for compensation in 2025-26, as there are about 890 cases before district legal services authorities that attract compensation when the cases are disposed of. The total amount required is around ₹40 to 45 crore, including around ₹30 crore required to clear those waiting for compensation since 2023. Duty of govt. The provisions of the CrPC and the BNSS vest a statutory duty on the State governments to release sufficient funds under the victims' compensation scheme (VCS), and the High Court of Karnataka, in a PIL petition filed in 2017 by People's Movement Against Sexual Assault, had given directions to the government to release funds to the KSLSA under VCS.
Miami Herald
05-05-2025
- Business
- Miami Herald
Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards
With six newly established, identical BSL-2 laboratories now operational, biologics CDMO Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks VILNIUS, LT / ACCESS Newswire / May 5, 2025 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral Clearance Studies (VCS) capabilities. This strategic growth follows the opening of Northway Biotech's new Gene Therapy Center with dedicated cGMP facilities for virus-related projects. With six newly established, identical BSL-2 laboratories now operational, Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks. Additionally, the company has expanded its capabilities to perform GMP-compliant manufacturing and testing under BSL-3 conditions, further strengthening its service offering across gene therapy and broader biologics development. Viral Clearance Studies are now offered both as part of Northway Biotech's integrated CDMO programs and as a standalone service. This flexibility allows external clients to access VCS expertise independently, without requiring a manufacturing agreement. Accelerated Delivery Timelines - Over One Month Faster Than Industry Leveraging expanded infrastructure and integrated analytical capabilities, Northway Biotech is positioned to deliver Viral Clearance Studies substantially faster than the current industry standard. Comprehensive studies, assessing viral removal and inactivation, can now be completed with final regulatory-compliant reporting in under 10 weeks from initiation of project design when two model viruses are employed, and within 12 weeks when four model viruses are used. "Our expansion into Viral Clearance Studies is a natural extension of our CDMO services, enabling us to manage these critical studies in-house and significantly reduce project timelines for our clients," said Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech. "By investing in state-of-the-art BSL-2 and BSL-3 facilities, expanding technical capabilities, and further strengthening our scientific teams, we are uniquely positioned to deliver high-quality VCS data faster - a key advantage for clients advancing through clinical development and regulatory approval." For more information on Northway Biotech's Viral Clearance Study processes, service offerings, and delivery timelines, please complete the contact form to connect with the Northway Biotech team. About Northway Biotech - Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA. Media & Business Contact: bd@ Prof. Vladas Algirdas BumelisCEO and Chairman of the BoardNorthway SOURCE: Northway Biotech press release
